Tag: $Dyne Therapeutics

Dyne Therapeutics stock falls after updated plan for accelerated approval in DM1

Dyne Therapeutics, Inc. (Nasdaq:DYN) stock fell 23% after the company announced an updated plan for obtaining U.S. Accelerated Approval for DYNE-101 in myotonic dystrophy type 1 (DM1) following a Type C meeting with the FDA.